Actuate Therapeutics

The company is a clinical biotech entity developing GSK-3 inhibitor drugs to treat metastatic pancreatic cancer. Incorporated in Delaware, it focuses on developing therapies for high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3).

Elraglusib (formerly 9-ING-41), a small molecule designed to enter cancer cells and block the function of the enzyme GSK-3β, a master regulator of complex biological signaling cascades including those mediated by oncogenes, is currently under development. This blockade of GSK-3β signaling is believed to result in the death of cancer cells and the regulation of anti-tumor immunity.

The company has exclusively licensed a portfolio of GSK-3 inhibitors developed in collaboration with the University of Illinois-Chicago (UIC) and Northwestern University (NU). The lead drug in this portfolio, elraglusib (9-ING-41), is being evaluated in a randomized Phase 2 trial in patients with metastatic pancreatic cancer, marking the most advanced clinical indication to date.